SLC5A2 and diabetic cardiomyopathy: Figure 4 shows a summary of SGLT2 inhibitor mechanisms to target renal glucose absorption (canonical) and cardiac mTORC1 signaling (non-canonical) in diabetic cardiomyopathy.